Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS
IntroductionMRTX1133 is a selective and reversible small molecule inhibitor of KRAS (G12D), which significantly delays the progression of solid tumors. However, no study on the absorption, distribution, and excretion of MRTX1133.MethodsA fast ultra-high performance liquid chromatography-tandem quadr...
Saved in:
| Main Authors: | Wei Lu, Rong Zeng, Meng Pan, Yuan Zhou, Huijuan Tang, Wanying Shen, Yijun Tang, Pan Lei |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1509319/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Study on the mechanism of KRAS R68G secondary mutation-induced resistance to KRASG12D-targeted inhibitor MRTX1133
by: WANG Gaoming, et al.
Published: (2025-06-01) -
Development and Validation of a UHPLC-MS/MS Method for Ciprofol Detection in Plasma: Application in Clinical Pharmacokinetic Studies
by: Zhu J, et al.
Published: (2025-07-01) -
MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis
by: Junwei Zou, et al.
Published: (2025-02-01) -
Investigation of potential KRASG12D inhibitors: a comparative study between MRTX1133 and natural compounds via computational structural biology approaches
by: Safiye Merve Bostancioglu, et al.
Published: (2025-07-01) -
Determination of QLNC-3A6 in canine plasma by UHPLC-MS/MS and its application in pharmacokinetic studies
by: Sumeng Chen, et al.
Published: (2024-12-01)